The Dog Cancer Survival Guide (139 page)

Perianal adenocarcinoma in the canine male: a retrospective study of 41 cases. Vail DM, Withrow SJ, Schwarz PD, Powers BE.
J Am Anim Hosp Assoc
26:329, 1990.

Hormone-dependent neoplasms of the canine perianal gland. Hayes HM, Wilson GP.
Cancer Res
37:2068, 1977.

Adenocarcinoma of the apocrine glands of the anal sac in dogs: a review of 32 cases. Ross JT, Scavelli TD, Matthiesen DT, Patnaik AK.
J Am Anim Hosp Assoc
27:349, 1991.

Canine anal sac adenocarcinomas: clinical presentation and response to therapy. Bennett PF, DeNicola DB, Bonney P, et al.
J Vet Intern Med
16:100, 2002.

Carcinoma of the apocrine glands of the anal sac in dogs: 113 cases (1985-1995). Williams LE, Gliatto JM, Dodge RK, et al.
J Am Vet Med Assoc
223:825, 2003

Late complications of pelvic irradiation in 16 dogs. Anderson CR, McNiel EA, Gillette EL, et al.
Vet Radiol Ultrasound
43:187, 2002.

Clinical stage, therapy and prognosis in canine anal sac gland carcinoma. Polton GA, Brearley MJ.
Vet Intern Med
21:274, 2007.

Identification of parathyroid hormone-related protein in canine apocrine adenocarcinoma of the anal sac. Rosol TJ, Capen CC, Danks JA, et al.
Vet Pathol
27:89, 1990.

Parathyroid hormone (PTH)-related protein, PTH, and 1,25-dihydroxyvitamin D in dogs with cancer-associated hypercalcemia. Rosol TJ, Nagode LA, Couto CG, et al.
Endocrinology
131:1157, 1992.

Cryosurgical treatment of perianal gland adenomas in the dog. Liska WD, Withrow SJ.
J Am Anim Hosp Assoc
14:457, 1978.

X-irradiation of perianal gland neoplasms in the dog. Morgan JP, Carlson WD.
J Am Vet Med Assoc
143:1227, 1963.

Surgery of metastatic anal sac adenocarcinoma in five dogs. Hobson HP, Brown MR, Rogers KS.
Vet Surg
35:267, 2006.

Postoperative radiotherapy and mitoxantrone for anal sac adenocarcinoma in the dog: 15 cases (1991–2001). Turek MM, Forrest LJ, Adams WM, et al.
Veterinary and Comparative Oncology
. 1:94–104. 2003

Prayer

Effects of remote, retroactive intercessory prayer on outcomes in patients with bloodstream infection: randomised controlled trial. Leibovici L.
BMJ.
2001 Dec 22-29;323(7327):1450-1.

Science, medicine, and intercessory prayer. Sloan RP, Ramakrishnan R.
Perspect Biol Med
. 2006 Autumn;49(4):504-14.

Does religious activity improve health outcomes? A critical review of the recent literature. Coruh B, Ayele H, Pugh M, Mulligan T.
Explore
(NY). 2005 May;1(3):186-91.

Intercessory prayer for the alleviation of ill health. Roberts L, Ahmed I, Hall S, Davison A.
Cochrane Database Syst Rev
. 2009 Apr 15;(2)

Radiation

Radiation therapy. Lattimer JC, Bommarito, et al, in Henry CJ, Higginbotham ML (ed):
Cancer Management in Small Animal Practice
. Missouri. Saunders Elsevier 2010, p 146-56.

Radiation therapy. LaRue SM, Gillette EL, in Withrow SJ, Vail DM (eds):
Withrow & MacEwen’s Small Animal Clinical Oncology
. Missouri, Saunders Elsevier, 2007, pp 193-210.

Four fraction palliative radiotherapy for osteosarcoma in 24 dogs. Green EM, Adams WM, Forrest LJ.
J Am Anim Hosp Assoc
38(5):445, 2002.

Palliative radiotherapy for canine appendicular osteosarcoma. McEntee MC, Page RL, Novotney CA, et al.
Vet Radiol Ultrasound
34:367, 1993.

Palliative radiotherapy of appendicular osteosarcoma in 95 dogs. Ramirez O 3rd, Dodge RK, Page RL, et al.
Vet Radiol Ultrasound
40:517, 1999.

Salt

Enhancing effects of dietary salt on both initiation and promotion stages of rat gastric carcinogenesis. Takahashi M and Hasegawa R.
Princess Takamatsu Symp
. 1985;16:169-82.

Dietary sodium chloride intake independently predicts the degree of hyperchloremic metabolic acidosis in healthy humans consuming a net acid-producing diet. Frassetto LA, Morris RC Jr, Sebastian A.
Am J Physiol Renal Physiol
. 2007 Aug;293(2):F521-5.

Silymarin/Silybinin

Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. Zhang S and Morris ME.
J Pharmacol Exp Ther
. 2003 Mar;304(3):1258-67.

Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. Scambia G, et al.
Eur J Cancer
. 1996 May;32A(5):877-82.

Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Flaig TW, et al.
Int J Cancer.
2007 May 1;120(9):2028-33.

The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2) Hardwick LJA, Velamakanni S, van Veen HW,
Br J Pharmacol
. 2007 May; 151(2): 163–174.

Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Raina K, et al.
Cancer Res.
2007 Nov 15;67(22):11083-91.

Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Singh RP, et al.
Clin Cancer Res.
2008 Jan 1;14(1):300-8.

Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Raina K, et al.
Cancer Res
. 2008 Aug 15;68(16):6822-30.

Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Dhanalakshmi S, et al.
Oncogene.
2002 Mar 7;21(11):1759-67.

Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Katiyar SK, Roy AM, Baliga MS.
Mol Cancer Ther
. 2005 Feb;4(2):207-16.

Multitargeted therapy of cancer by silymarin. Ramasamy K and Agarwal R.
Cancer Lett
. 2008 Oct 8;269(2):352-62. Epub 2008 May 9.

Comparative bioavailability of silibinin in healthy male volunteers. Kim YC, et al.
Int J Clin Pharmacol Ther
. 2003 Dec;41(12):593-6.

Silibinin activates p53-caspase 2 pathway and causes caspasemediated cleavage of Cip1/p21 in apoptosis induction in bladder transitional-cell papilloma RT4 cells: evidence for a regulatory loop between p53 and caspase 2. Tyagi A, et al.
Carcinogenesis.
2006 Nov;27(11):2269-80.

Silymarin causes caspases activation and apoptosis in K562 leukemia cells through inactivation of Akt pathway. Zhong X, et al.
Toxicology
. 2006 Oct 29;227(3):211-6.

Inhibition of P-glycoprotein by natural products in human breast cancer cells. Chung SY, et al.
Arch Pharm Res.
2005 Jul;28(7):823-8.

Influence of silymarin and its flavonolignans on doxorubiciniron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. Psotová J, et al.
Phytother Res.
2002 Mar;16 Suppl 1:S63-7.

Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy. Comelli MC, et al.
Integr Cancer Ther
. 2007 Jun;6(2):120-9.

Effect of silibinin on the growth and progression of primary lung tumors in mice. Singh RP, et al.
J Natl Cancer Inst
. 2006 Jun 21;98(12):846-55.

Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Singh RP, et al.
Clin Cancer Res
. 2008 Dec 1;14(23):7773-80.

Sleep. Melatonin, and Cancer

Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Blask DE, Sauer LA, Dauchy RT.
Curr Top Med Chem
. 2002 Feb;2(2):113-32. Review.

Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor- mediated signal transduction events. Blask DE, et al.
Cancer Res
. 1999 Sep 15;59(18):4693-701.

New actions of melatonin on tumor metabolism and growth. Blask DE, et al.
Biol Signals Recept.
1999 Jan-Apr;8(1-2):49-55. Review.

Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Blask DE, Dauchy RT, Sauer LA.
Endocrine
. 2005 Jul;27(2):179-88. Review.

Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Blask DE, Sauer LA, Dauchy RT.
Curr Top Med Chem
. 2002 Feb;2(2):113-32. Review.

Therapeutic actions of melatonin in cancer: possible mechanisms. Srinivasan V, et al.
Integr Cancer Ther
. 2008 Sep;7(3):189- 203. Review.

Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women. Blask DE et al.
Integr Cancer Ther
. 2009 Dec;8(4):347- 53.

A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. Lissoni P, et al.
J Pineal Res.
1997 Aug;23(1):15-9.

Melatonin in cancer management: progress and promise. Jung B and Ahmad N.
Cancer Res
. 2006 Oct 15;66(20):9789-93.

Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. Mills E, Wu P, Seely D, Guyatt G.
J Pineal Res
. 2005 Nov;39(4):360-6.

Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Reiter RJ, et al.
Crit Rev Oncog
. 2007 Dec;13(4):303-28.

Lighting for the human circadian clock: recent research indicates that lighting has become a public health issue. Pauley SM.
Med Hypotheses
. 2004;63(4):588-96.

The modulatory role of melatonin on immune responsiveness. Carrillo-Vico A, et al.
Curr Opin Investig Drugs
. 2006 May;7(5):423-31.

Melatonin, immune function and aging. V Srinivasan, et al.
Immun Ageing
. 2005; 2: 17.

Melatonin for refractory idiopathic thrombocytopenic purpura: a report of 3 cases. Todisco M, Rossi N.
Am J Ther
. 2002 Nov-Dec;9(6):524-6.

Melatonin makes splenectomy unnecessary in two patients with idiopathic thrombocytopenic purpura refractory to corticosteroids. Todisco M.
J Pineal Res
. 2007 Sep;43(2):214.

Soft Tissue Sarcomas

Soft Tissue Sarcomas. Selting KA, in Henry CJ, Higginbotham ML (ed):
Cancer Management in Small Animal Practice
. Missouri. Saunders Elsevier 2010, p 321-325.

Soft Tissue Sarcomas. Liptak JM, Forrest LJ. Withrow SJ, Vail DM (eds):
Withrow & MacEwen’s Small Animal Clinical Oncology
. St Louis Missouri, Saunders Elsevier, 2007, pp 425-454.

Soft-Tissue Sarcomas. Farrelly J, in Cote E (2
^nd
ed),
Clinical Veterinary Advisor: Dogs and Cats
. Missouri, Mosby Elsevier, 2011, p 1064-1035.

Management of Soft Tissue Sarcomas. Rassnick KM.
Vet Clin Small Anim
33: 517-531, 2003.

Principles of treatment for Soft-Tissue Sarcomas in the dog. Ettinger SN.
Clin Tech Small Anim Pract
18:118-122, 2003.

Prognostic significance of intratumoral microvessel density in canine soft-tissue sarcomas. Luong RH, Baer KE, Craft DM, Ettinger SN, et al.
Vet Pathol
. 43(5):622-31. 2006

Association of argyrophilic nucleolar organizing regions, Ki- 67, and proliferating cell nuclear antigen scores with histologic grade and survival in dogs with soft tissue sarcomas: 60 cases (1996-2002). Ettinger SN, Scase TJ, Oberthaler KT, et al.
J Am Vet Med Assoc
. 228(7):1053-62. 2006

Prognostic factors for surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986-1996). Kuntz CA, Dernell WS, Powers BE, et al.
J Am Vet Med Assoc
211: 1147-1151, 1997